CN Patent

CN105294650A — 一种Ceritinib化合物及其药物组合物

Assigned to Jiangsu Aosaikang Pharmaceutical Co Ltd · Expires 2016-02-03 · 10y expired

What this patent protects

本发明属于医药化学领域，本发明公开了Ceritinib化合物的晶体形式及其药物组合物。该化合物具有稳定性高的特点，符合药用的要求。本发明提供制备工艺稳定，重现性好，符合工业化大生产的要求。

USPTO Abstract

本发明属于医药化学领域，本发明公开了Ceritinib化合物的晶体形式及其药物组合物。该化合物具有稳定性高的特点，符合药用的要求。本发明提供制备工艺稳定，重现性好，符合工业化大生产的要求。

Drugs covered by this patent

Patent Metadata

Patent number
CN105294650A
Jurisdiction
CN
Classification
—
Expires
2016-02-03
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Aosaikang Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.